H.C. Wainwright Reiterates Buy Rating on Lyell Immunopharma (LYEL)

June 3, 2026 6:55 AM

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $45.00 price target on Lyell Immunopharma (NASDAQ: LYEL).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found